Amgen Inc. (BCBA:AMGN)

Market Cap	256.41T
Revenue (ttm)	49.30T
Net Income (ttm)	9.60T
Shares Out	n/a
EPS (ttm)	17,725.81
PE Ratio	26.71
Forward PE	16.20
Dividend	180.33 (1.09%)
Ex-Dividend Date	Nov 21, 2025

Volume	832
Average Volume	3,848
Open	16,570
Previous Close	16,770
Day's Range	16,560 - 16,800
52-Week Range	9,500 - 17,070
Beta	n/a
RSI	66.06
Earnings Date	Nov 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD